The role of Buserelin in the treatment of advanced prostate cancer (APC)
https://doi.org/10.21518/2079-701X-2015-8-47-49
Abstract
Hormonal therapy is the key method in the treatment of locally advanced and metastatic APC. 142 patients with APC treated with LHRH analogues were followed up from December 2011 till December 2014. The efficacy and tolerability of Buserelin-depo was compared with other LHRH analogues. Both Buserelin and such expensive foreign drugs as goserelin, leuprorelin and triptorelin demonstrated high efficacy and tolerability in the treatment of hormone-dependent APC.
About the Authors
S. V. Mishugin
Vishnevsky Institute of Surgery, Moscow
Russian Federation
Russian Federation
A. A. Drobyazko
Vishnevsky Institute of Surgery, Moscow
Russian Federation
Russian Federation
A. A. Mordovin
Vishnevsky Institute of Surgery, Moscow
Russian Federation
Russian Federation
A. A. Gritskevich
Vishnevsky Institute of Surgery, Moscow
Russian Federation
Russian Federation
I. G. Rusakov
City Clinical Hospital No. 57, Moscow
Russian Federation
Russian Federation
References
1. Huggins C, Hodges CV. Studies on prostatic cancer. II The effect of castration, estrogen and androgen injections on ser um. Cancer Res 1944;1: 293-297.
2. Oefelein MG, Feng A, Scolieri MJ et al. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000; 56: 1021-4.
3. Evans CP, Fleshner N, Fitzpatrick JM et al. An evidence - base approach to understanding the harmacological class effect in the management of prostatic diseases. BJU Int 2005; 95: 742-9.
4. Seidenfeld J, Samson DJ, Hasselblad V et al. Single - therapy androgen suppression in men with advanced prostate cance r: a systematic rewiew and meta - analysis. Annals of Internal Medicine , 2000, 132, 7, 566 - 577.
5. Anderson J, Abrahamsson PA, Crawford D et al. Management of advanced prostate cancer: can we improve on androgen deprivation therapy. BJU Int 2008; 101:1497-1501.
6. Heidenreich A, Pfister D, Ohlamann CH et al. Androgen deprivation for advanced prostate cancer. Urologe 2008; 47: 270 - 83.
7. Klioze SS, Miller MF, Spiro TP. A randomized, comparative study of buserelin with DES/ orchiectomy in the treatment of stage D2 pro static cancer patients. Am J Clin Oncol 1988; 11 (Suppl 2): 17 -182
8. Huben RP, Murphy GP. A comparison of diethylstilbestrol or orchiectomy with buserelin and with methotrexate plus diethylbestrol or orchiectomy in newly diagnosed patients with clinical stage D2 cancer of the prostate. Cancer1988; 62:1881-
Review
For citations:
Mishugin SV, Drobyazko AA, Mordovin AA, Gritskevich AA, Rusakov IG. The role of Buserelin in the treatment of advanced prostate cancer (APC). Meditsinskiy sovet = Medical Council. 2015;(8):47-49. (In Russ.) https://doi.org/10.21518/2079-701X-2015-8-47-49
Views:
412
Email this article 